BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33444077)

  • 1. Comparative expression profile of CD10 and cyclin D1 in cutaneous histiocytofibroma and dermatofibrosarcoma.
    Kouki N; Ben Rejeb S; Cherif I; Ghozzi A; Chelly I; Bellil K; Haouet S
    J Immunoassay Immunochem; 2021 Jul; 42(4):347-358. PubMed ID: 33444077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
    Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
    Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
    Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
    Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
    Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
    Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
    Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
    Taniuchi K; Yamada Y; Nonomura A; Takehara K
    J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
    West KL; Cardona DM; Su Z; Puri PK
    Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans.
    Kutzner H; Mentzel T; Palmedo G; Hantschke M; Rütten A; Paredes BE; Schärer L; Guillen CS; Requena L
    Am J Surg Pathol; 2010 Feb; 34(2):190-201. PubMed ID: 20061935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
    Park S; Cho S; Kim M; Park JU; Jeong EC; Choi E; Park JH; Lee C; Chang MS
    J Am Acad Dermatol; 2018 Nov; 79(5):843-852. PubMed ID: 29792909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.
    Garcia C; Viehman G; Hitchcock M; Clark RE
    Dermatol Surg; 1996 Feb; 22(2):177-9. PubMed ID: 8608381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors.
    Llombart B; Monteagudo C; Sanmartín O; López-Guerrero JA; Serra-Guillén C; Poveda A; Jorda E; Fernandez-Serra A; Pellín A; Guillén C; Llombart-Bosch A
    J Am Acad Dermatol; 2011 Sep; 65(3):564-575. PubMed ID: 21570152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
    Okita H; Ohtsuka T; Yamazaki S
    Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas.
    Szollosi Z; Scholtz B; Egervari K; Nemes Z
    J Clin Pathol; 2007 Feb; 60(2):190-4. PubMed ID: 16731589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
    Abdaljaleel MY; North JP
    Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
    Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
    Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
    Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
    Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
    Li N; McNiff J; Hui P; Manfioletti G; Tallini G
    Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pediatric case of dermatofibrosarcoma protuberans: an immunohistochemical study.
    Patrizi A; Vespignani F; Fraternali GO; Neri I
    Pediatr Dermatol; 2000; 17(1):29-33. PubMed ID: 10720984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dermatofibrosarcoma Darier and Ferrand. Immunohistochemistry study of 38 cases. Research on a specific marker].
    Declerck D; Claye C; Rotteleur G; Lecomte-Houcke M
    Ann Pathol; 1997 Oct; 17(5):324-8. PubMed ID: 9471146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the CD10 antigen (neutral endopeptidase) by mesenchymal tumors of the skin.
    Kanitakis J; Bourchany D; Claudy A
    Anticancer Res; 2000; 20(5B):3539-44. PubMed ID: 11131659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.